DTC Advertising Under Pressure
Direct to consumer advertising is a double-edged sword for pharma manufacturers: It boosts sales of their products, but it also leaves them vulnerable to negative public perception. In the eight years since the FDA first permitted DTC for durgs, the noted benefits have largely outweighed the potential for damage. But several factors are combining to shift the equation and now even proponents are clamoring for change. IN VIVO interviews industry experts to get their opinion of the current status and future direction of DTC.
You may also be interested in...
Pfizer was vague in describing to analysts just how it would reduce costs by $4 billion per year by 2008. The FDA's announcement that it had asked Pfizer to remove the Cox-2 inhibitor Bextra from the market just days later complicates matters for the pharmaceutical giant. In any case, those hoping for a significant headcount reduction among Pfizer sales reps were surely disappointed.
As important as the news that came out of the Cox-2 advisory panel hearings was the subtext: the industry's increasing loss of control over its marketing messages.
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.